Dublin, Sept. 29, 2023 (GLOBE NEWSWIRE) -- The "Scleroderma Diagnostics and Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global Scleroderma Diagnostics and Therapeutics market is poised for substantial growth, with an estimated value of $2 billion in 2022, projected to soar to $2.8 billion by 2030. This lucrative market presents significant opportunities for investors, strategists, and healthcare professionals seeking to make a meaningful impact in the dynamic realm of medical research.
This comprehensive research report goes beyond data; it's a strategic tool that provides in-depth insights into the Scleroderma market. By delving into key segments like 'Localized' and 'Systemic,' stakeholders gain critical insights into upcoming opportunities and challenges. Moreover, it offers a competitive advantage by dissecting the U.S. market, valued at $592.9 million, and China's burgeoning market, set to reach an estimated $486.3 million by 2030. The report also offers detailed intelligence on leading global competitors, unveiling their strategies and market share. To stay abreast of the rapidly evolving healthcare landscape, secure your copy of this report today.
Key Questions Answered by the Report:
- What is the current size and future forecast of the Global Scleroderma Diagnostics and Therapeutics Market?
- The Global Scleroderma Diagnostics and Therapeutics Market is projected to reach $2.8 billion by 2030, growing at a CAGR of 4.2% from 2022 to 2030.
- Which segments are driving this growth, and what are their growth rates?
- The 'Localized' segment is projected to record a robust 4.6% CAGR, reaching $1.8 billion by 2030. Additionally, the 'Systemic' segment is expected to exhibit a readjusted growth rate of 3.6%.
- Which countries are pivotal players in this market?
- The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at $592.9 million in 2022, while China is forecast to grow at a CAGR of 3.8% to reach $486.3 million by 2030. Other noteworthy geographic markets include Japan and Canada, each projected to grow at 3.7% and 3.6%, respectively, over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.
This comprehensive market analysis focuses on the field of scleroderma diagnostics and therapeutics, covering various geographic regions, including the USA, Canada, Japan, China, Europe, Asia-Pacific, and the Rest of the World. It offers an independent assessment of annual sales in US$ Thousand from 2022 through 2030, along with corresponding percentage Compound Annual Growth Rates (% CAGR). The report also includes a historical review of sales in the scleroderma diagnostics and therapeutics market from 2014 to 2021, providing insights into past trends and growth rates.
Additionally, the analysis offers a 16-year perspective, highlighting significant years such as 2014, 2023, and 2030, illustrating the evolving landscape of scleroderma diagnostics and therapeutics across different regions. The market is segmented into various categories, including immunosuppressive agents, endothelin receptor antagonists, and other drug classes, providing a comprehensive view of the market's diverse aspects. Moreover, it separates the market into localized and systemic scleroderma, offering valuable data for industry stakeholders to make informed decisions in the dynamic field of scleroderma diagnostics and therapeutics.
Select Competitors (Total 42 Featured)
- Actelion Pharmaceuticals Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Corbus Pharmaceuticals Holdings, Inc.
- Cumberland Pharmaceuticals, Inc.
- Cytori Therapeutics, Inc.
- Gilead Sciences, Inc.
- Pfizer, Inc.
- Sanofi SA
What's New for 2023?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 194 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value (USD) in 2022 | $2 Billion |
| Forecasted Market Value (USD) by 2030 | $2.8 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/gnbiw9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
